Moreover, CSN5i-3, a novel selective and orally available CSN5 inhibitor, significantly inhibits SRC family signaling (such as SRC and YES), showing potential therapeutic effects in prostate cancer (Mazzu et al., 2022). Here, SRC is linked to prostate carcinoma.